40 Participants Needed

ssNPA Device for Upper Airway Obstruction

LO
DZ
DA
LM
Overseen ByLouise M O'Brien, PhD
Age: < 65
Sex: Any
Trial Phase: Academic
Sponsor: University of Michigan
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 2 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores the effectiveness of a new device, the Self-Supporting Nasopharyngeal Airway (ssNPA), for children with obstructive sleep apnea due to Hypotonic Upper Airway Obstruction (HUAO). The researchers aim to determine if this device can alleviate common symptoms such as snoring, daytime sleepiness, or hyperactivity. Participants will either use the ssNPA device or continue with their usual care while awaiting another treatment option. Children who have had their tonsils removed or cannot undergo this surgery, yet still experience significant sleep issues, may be suitable candidates. As an unphased trial, this study provides a unique opportunity for children to potentially benefit from an innovative treatment option.

Will I have to stop taking my current medications?

The trial information does not specify whether participants need to stop taking their current medications.

What prior data suggests that the ssNPA device is safe for treating upper airway obstruction in children?

Research shows that the Self-Supporting Nasopharyngeal Airway (ssNPA) device is generally safe for treating breathing problems in people with low muscle tone. In earlier studies, patients using the ssNPA device did not report any serious side effects. Some individuals might worry about comfort, as it may feel strange initially. However, no major safety issues have emerged.

The device helps keep the airway open during sleep and is especially aimed at children with obstructive sleep apnea, a condition where breathing stops and starts during sleep. Although data is limited, available research suggests that most patients can use the ssNPA device without significant problems.

Overall, the ssNPA device appears to be a safe option, but discussing any concerns with a healthcare provider is important. They can offer advice based on individual needs and conditions.12345

Why are researchers excited about this trial?

The Self-Supporting Nasopharyngeal Airway (ssNPA) is unique because it offers an innovative approach to managing upper airway obstruction, differing significantly from standard treatments like positive airway pressure (PAP) devices. Unlike traditional options that rely on external machines to maintain airflow, the ssNPA is a self-supporting device, which means it physically keeps the airway open without the need for external power or machines. Researchers are excited about this treatment because it could provide a more convenient and less cumbersome solution for patients, potentially improving compliance and comfort. Furthermore, ssNPA’s simple design allows for easier use, making it particularly promising for individuals who struggle with complex equipment.

What evidence suggests that the ssNPA device is effective for obstructive sleep apnea?

Research shows that the Self-Supporting Nasopharyngeal Airway (ssNPA) device, which participants in this trial may receive, can help treat obstructive sleep apnea (OSA), a condition where the airway blocks during sleep. Studies have found that the ssNPA device can lower the Apnea/Hypopnea Index (AHI), which measures the severity of sleep apnea. Patients report that the device is comfortable and easy to use, making it a good option for those with weakened upper airway muscles. The ssNPA could serve as an alternative to more invasive treatments like surgery or a tracheostomy. Although not widely used yet, early research suggests it can be a useful tool for managing airway blockage.12467

Who Is on the Research Team?

DA

David Zopf, MD

Principal Investigator

The University of Wisconsin

LM

Louise O'Brien, PhD

Principal Investigator

University of Michigan

Are You a Good Fit for This Trial?

This trial is for children with Hypotonic Upper Airway Obstruction and obstructive sleep apnea who've had a tonsillectomy or can't have one. They must show symptoms like snoring, daytime sleepiness, or hyperactivity. Kids with severe breathing issues during sleep, bleeding disorders, certain airway collapses, active COVID-19 infection, or those on blood thinners cannot join.

Inclusion Criteria

I experience symptoms like snoring, daytime sleepiness, or hyperactivity.
My child has severe sleep apnea or breathing issues at night confirmed by a sleep study.
I have had my tonsils removed or cannot have them removed due to health reasons.
See 2 more

Exclusion Criteria

I have a lung condition that restricts my breathing.
I have a medical condition that makes using a nasal airway support unsuitable.
You have a medical or social situation that could make it hard for you to follow the study plan or attend follow-up appointments. Some psychiatric conditions, like ADHD or conduct disorder, won't be excluded, but severe autism will be excluded.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Waitlist Control

Participants are placed on a waitlist for positive airway pressure (PAP) for 8 weeks

8 weeks

Treatment

Participants receive the Self-Supporting Nasopharyngeal Airway (ssNPA) device

8 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Self-Supporting Nasopharyngeal Airway (ssNPA)
Trial Overview The study tests if the Self-Supporting Nasopharyngeal Airway (ssNPA) device helps treat obstructive sleep apnea in kids with muscle hypotonia affecting their upper airways. It's an alternative to traditional treatments post adenotonsillectomy.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Self-Supporting Nasopharyngeal Airway (ssNPA)Experimental Treatment1 Intervention
Group II: Standard of CareActive Control1 Intervention

Self-Supporting Nasopharyngeal Airway (ssNPA) is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Self-Supporting Nasopharyngeal Airway for:
🇪🇺
Approved in European Union as Self-Supporting Nasopharyngeal Airway for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Michigan

Lead Sponsor

Trials
1,891
Recruited
6,458,000+

National Institutes of Health (NIH)

Collaborator

Trials
2,896
Recruited
8,053,000+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+

Published Research Related to This Trial

The oropharyngeal airway (OPA) is generally considered a safe device for aiding in mask ventilation, having been used since 1933.
However, there is a rare risk of aspiration leading to severe complications, such as near total upper airway obstruction, highlighting the need for careful placement and monitoring during use.
Aspiration of an oropharyngeal airway during nasotracheal intubation.Lee, CM., Song, KS., Morgan, BR., et al.[2022]
The new self-retaining nasopharyngeal airway was tested in 100 patients during anesthesia with spontaneous respiration, demonstrating its clinical effectiveness.
In addition to its intended nasal use, the airway can also function as a self-retaining oropharyngeal airway, expanding its versatility in clinical settings.
The cuffed pharyngeal airway.Feldman, SA., Fauvel, NJ., Ooi, R.[2007]
The study found that reduced upper airway dimensions during sleep are linked to lower sleep efficiency, highlighting the importance of airway size in sleep quality.
The nasopharyngeal appliance (NPA) was shown to be more effective than the mandibular repositioning splint (MRS) in improving outcomes for patients with upper airway resistance syndrome (UARS).
Upper airway dimensions and sleep efficiency--three-dimensional imaging analysis and assessment of the nasopharyngeal appliance.Venkat, R., Vasanthakumar, M., Balakrishnan, D., et al.[2015]

Citations

Pilot Study of a Self-Supporting Nasopharyngeal Airway in ...OSA is characterized by recurrent episodes of partial or complete upper airway obstruction during sleep with associated arousals and/ or oxygen desaturations.
Self-Supported Nasopharyngeal Airway Device for ...Results show that ssNPA has demonstrated the good tolerability and feasibility of effectively treating OSA in both patients, and Apnea/Hypopnea Index (AHI) was ...
3.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/35866230/
Novel treatment for hypotonic airway obstruction and ...A long-term NPA device may be an alternative or temporizing option to continuous positive airway pressure, upper airway surgery, or tracheostomy.
Pilot Study of a Self-Supporting Nasopharyngeal Airway in ...Although an NPA is shown to be safe and effective, very few patients currently receive the treatment due to the perceived decrease in quality-of-life for the ...
zopf, david adam - NIH RePORTEROur multidisciplinary team has developed a dramatically effective non-surgical nasopharyngeal airway stent that has demonstrated good tolerability in hypotonic ...
Self-Supported Nasopharyngeal Airway Device for ...Hypotonic patients may show signs of motor skill delay, along with hypermobile or hyperflexible joints, speech difficulties, poor reflexes, decreased strength,.
Novel treatment for hypotonic airway obstruction and ...Two patients used a safety pin and tape attachment, and two patients used a novel 3D-printed, self-supporting nasal securement. All 4 patients had ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security